Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors

Diabetes - GeneralType 2 Diabetes

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Lancet Diabetes Endocrinol.

Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A

doi: 10.1016/

COMMENTED

Type 2 Diabetes

Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Diabetes Obes Metab.

Mantsiou C, Karagiannis T, Kakotrichi P, Malandris K, Avgerinos I, Liakos A, Apostolos Tsapas, Bekiari E

doi: 10.1111/dom.14108.

COMMENTED

Type 2 Diabetes

Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Diabetes Res Clin Pract.

Patoulias D, Stavropoulos K, Imprialos K, Katsimardou A, Kalogirou MS, Koutsampasopoulos K, Zografou I, Papadopoulos C, Karagiannis A, Doumas M

doi: 10.1016/j.diabres.2019.107927.

Type 2 Diabetes

Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis

Diabet Med.

Hussein H, Zaccardi F, Khunti K, Seidu S, Davies MJ, Gray LJ

doi: 10.1111/dme.

COMMENTED

Type 2 Diabetes

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Circulation.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS

doi: 10.1161/CIRCULATIONAHA.

Type 2 Diabetes

Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

Cardiovasc Diabetol

Real J, Vlacho B, Ortega E, Vallés JA, Mata-Cases M, Castelblanco E, Wittbrodt ET, Fenici P, Kosiborod M, Mauricio D, Franch-Nadal J

doi: 10.1186/s12933-021-01323-5

Diabetes - GeneralType 2 Diabetes

Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review

J Am Coll Cardiol.

Zelniker TA, Braunwald E

doi: 10.1016/j.jacc.2018.06.040.

Type 2 Diabetes

Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes

Diabetes Obes Metab

Kohsaka S, Takeda M, Kidani Y, Yajima T

doi: 10.1111/dom.14289

COMMENTED

Diabetes - GeneralType 2 Diabetes

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes

JAMA Intern Med.

Chang HY, Singh S, Mansour O, Baksh S, Alexander GC

doi: 10.1001/jamainternmed.

Related content

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis

Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials

Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review

Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes